Search Results

MD2-IN-1 5 mg  | 99.43%

TargetMol

MD2-IN-1 is a Myeloid differentiation protein 2 (MD2) inhibitor with a KD of 189  μM for the recombinant human MD2 (rhMD2).

More Information Supplier Page

MD2-IN-1 1 mg  | 99.43%

TargetMol

MD2-IN-1 is a Myeloid differentiation protein 2 (MD2) inhibitor with a KD of 189  μM for the recombinant human MD2 (rhMD2).

More Information Supplier Page

AZD3759 hydrochloride 5 mg  | Purity Not Available

TargetMol

AZD3759 (hydrochloride) is an effective, orally active and central nervous system-penetrant EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.2/0.3/0.2 nM for EGFR (L858R)/EGFR (wt)/EGFR (exon 19Del).

More Information Supplier Page

Romidepsin 10 mg  | 99.53%

TargetMol

Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T cell lymphomas.

More Information Supplier Page

Romidepsin 1 mg  | 99.53%

TargetMol

Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T cell lymphomas.

More Information Supplier Page

XL388 2 mg  | 99.39%

TargetMol

XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases.

More Information Supplier Page

XL388 25 mg  | 99.39%

TargetMol

XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases.

More Information Supplier Page

XL388 10 mg  | 99.39%

TargetMol

XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases.

More Information Supplier Page